Subscribe
pavel-kapysh-lundbeck
Pavel Kapysh / Shutterstock.com
30 March 2021EuropeAlex Baldwin

Lundbeck loses €150m pay-for-delay appeal

Lundbeck has lost an appeal to the  Court of Justice of the European Union (CJEU) to waive €150 million ($176 million) in fines levied against itself and a group of five generics manufacturers over ‘pay-for-delay’ deals for its antidepressant generics.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Generics
Why the ‘first penguin’ of pay for delay has not come in Japan: anatomy of a Japan paradox
27 May 2022   Why does Japan have no reverse payments culture? Takanori Abe of Abe & Partners unpicks a complex issue.
Big Pharma
EU General Court backs Lundbeck fine in pay-for-delay case
12 September 2016   The EU General Court has backed the European Commission’s decision to fine pharma company Lundbeck and a number of generic producers.
Big Pharma
AG advises CJEU to uphold €94 million pay-for-delay fine
5 June 2020   The advocate general has recommended that the Court of Justice of the European Union uphold an almost €94 million fine imposed on Lundbeck for its pay-for-delay scheme.


Editor's picks

Europe
UPC confirms validity of Edwards Lifesciences heart valve tech patent
23 July 2024

Editor's picks

Europe
UPC confirms validity of Edwards Lifesciences heart valve tech patent
23 July 2024
Americas
New-look WIPR Leaders 2024 is ‘most rigorous’ yet
2 July 2024
Americas
Earthquake Chevron: A massive shock to the system?
2 July 2024
Americas
Amarin wins appeal to advance ‘skinny label’ suit over Hikma generic
27 June 2024
Biotechnology
Guardant Health files suit against Tempus AI
13 June 2024
Big Pharma
Roche fires lawsuit at Sinocare unit over blood glucose test strip patents
6 June 2024

More on this story

Generics
Why the ‘first penguin’ of pay for delay has not come in Japan: anatomy of a Japan paradox
27 May 2022   Why does Japan have no reverse payments culture? Takanori Abe of Abe & Partners unpicks a complex issue.
Big Pharma
EU General Court backs Lundbeck fine in pay-for-delay case
12 September 2016   The EU General Court has backed the European Commission’s decision to fine pharma company Lundbeck and a number of generic producers.
Big Pharma
AG advises CJEU to uphold €94 million pay-for-delay fine
5 June 2020   The advocate general has recommended that the Court of Justice of the European Union uphold an almost €94 million fine imposed on Lundbeck for its pay-for-delay scheme.

More on this story

Generics
Why the ‘first penguin’ of pay for delay has not come in Japan: anatomy of a Japan paradox
27 May 2022   Why does Japan have no reverse payments culture? Takanori Abe of Abe & Partners unpicks a complex issue.
Big Pharma
EU General Court backs Lundbeck fine in pay-for-delay case
12 September 2016   The EU General Court has backed the European Commission’s decision to fine pharma company Lundbeck and a number of generic producers.
Big Pharma
AG advises CJEU to uphold €94 million pay-for-delay fine
5 June 2020   The advocate general has recommended that the Court of Justice of the European Union uphold an almost €94 million fine imposed on Lundbeck for its pay-for-delay scheme.

More features

Chinese biotech takes out US rival’s nucleic acid patent at PTAB
Lewis Roca promotes tech expert to managing partner
Panitch Schwarze brings in molecular biologist
US targets ‘product hopping’ with biologic litigation curbs
UPC confirms validity of Edwards Lifesciences heart valve tech patent
ITC concludes row over biotech lab equipment between US and German rivals
UKIPO launches ‘revolutionary’ patent filing and AI tool
USPTO clarifies AI's role in patent eligibility